News & Updates

The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.

Drinking wine in moderation may lower the risk of developing type 2 diabetes (T2D) and even yield some cardiovascular benefits in people with T2D, suggests a study.

Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.